Thursday, 22 August 2019

Kibow® to develop LBP to slow dialysis progression

25 July 2019 | News

Kibow® Biotech focuses on supporting and maintaining healthy kidney function with probiotics/prebiotics to potentially delay the progression to dialysis is based on its enteric toxin reduction platform technology

As a pioneer in the Enteric Dialysis® platform technology, Kibow® Biotech's mission has always been in conjunction with the standard care of therapy. The company's kidney health supplement product was developed to support normal kidney function which may help to slow the progression of kidney function in all stages of Chronic Kidney Disease (CKD) and potentially help a better outcome for dialysis patients worldwide.

Kibow® Biotech Inc is proud to announce that throughout its 22 years of operation, the focus on supporting and maintaining healthy kidney function with probiotics/prebiotics to potentially delay the progression to dialysis is based on its enteric toxin reduction platform technology termed "Enteric Dialysis®". Since 2005, Kibow® has been a pioneer and leader in the presently marketed kidney health supplement product, Renadyl™*.

Kibow® has been participating and exhibiting at various nephrology and medical professional annual meetings, like the American Society of Nephrology (ASN), National Kidney Foundation (NKF), American Association of Kidney Patients (AAKP), World Congress of Nephrology (WCN) and several other professional medical conferences since 2005. Kibow®Biotech's participation in these events is intended to educate nephrology and all other medical professionals about the emerging importance and crucial role of probiotics/prebiotics, gut-kidney connection, dysbiosis, and modulation of the Gut Microbiome with its innovative "Enteric Dialysis®" platform technology.

Kibow® is committed to improving kidney health in patients with kidney problems, not only for Americans but in all countries worldwide. Although marketed and sold as a dietary supplement product, Renadyl™ is the first and only kidney health supplement developed and formulated based on clinical results that utilizes Kibow® Biotech's patented and revolutionary "Enteric Dialysis®" technology.

Even before President Trump's announcement of an ambitious plan to change treatment for kidney disease in the United States, Kibow® Biotech has been taking steps to reach and improve more patients' lives by diversifying Renadyl™ from health supplement to a novel live biotherapeutic drug product (micro-organisms) and obtaining approval as a new drug product. As an FDA-approved human drug, Renadyl™ will be able to be marketed based on specific health benefit claims which should lead to greater acceptance by healthcare professionals. 

It will also pave the way for its medical reimbursement and could result in lower co-payment cost – both from private insurers and federal Medicare/Medicaid authorities. In addition to maintaining normal kidney function and slowing the progression of kidney disease, the goal would be to delay the need for expensive, physically and mentally taxing dialysis therapy. As a LBP drug product,

Renadyl™ may also be potentially useful in reducing the duration or frequency of dialysis with significantly improved quality of life and help save several billions of dollars spent not only in the USA but worldwide.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account